Fig. 3 | British Journal of Cancer

Fig. 3

From: Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients

Fig. 3

NMIBC (TaT1) patients with reduced GAS5 levels are at significant higher risk for short-term disease recurrence and progression. a–c Box plots presenting the correlation of GAS5 levels with NMIBC patients’ stage and grade (a), EORTC-risk group (b) and recurrence at the first follow-up cystoscopy (FFC) (c) of the screening cohort. p-Values calculated by Kruskal–Wallis test (a, b) and Mann–Whitney U-test (c). d–f Kaplan–Meier survival curves for the disease-free survival (DFS) and progression-free survival (PFS) of the NMIBC (TaT1) patients, as well as the overall survival (OS) of the MIBC (T2–T4) patients according to GAS5 levels in the screening cohort. g Kaplan–Meier survival curves for the progression-free survival (PFS) of the NMIBC (TaT1) patients according to GAS5 levels in the Hedegaard et al. validation cohort. h Kaplan–Meier survival curves for the overall survival (OS) of the MIBC (T2–T4) patients according to GAS5 levels in the TCGA provisional validation cohort. p-Values of the Kaplan–Meier survival analysis calculated by log-rank test

Back to article page